Lrig1 Is an Estrogen-Regulated Growth Suppressor and Correlates With Longer Relapse-Free Survival in ER -Positive Breast Cancer

Molecular Cancer Research - United States
doi 10.1158/1541-7786.mcr-11-0227
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Moesin Is an Independent Prognostic Marker for ER‑positive Breast Cancer

Oncology Letters
Cancer ResearchOncology
2018English

ER-α36-Mediated Rapid Estrogen Signaling Positively Regulates ER-Positive Breast Cancer Stem/Progenitor Cells

PLoS ONE
Multidisciplinary
2014English

Intratumoral Expression of CCR3 in Breast Cancer Is Associated With Improved Relapse-Free Survival in Luminal-Like Disease

Oncotarget
Oncology
2016English

High IKKα Expression Is Associated With Reduced Time to Recurrence and Cancer Specific Survival in Oestrogen Receptor (ER)-positive Breast Cancer

International Journal of Cancer
Cancer ResearchOncology
2017English

EZH2-Regulated DAB2IP Is a Medulloblastoma Tumor Suppressor and a Positive Marker for Survival

Clinical Cancer Research
Cancer ResearchOncology
2012English

Maximum Growth and Survival of Estrogen Receptor-Alpha Positive Breast Cancer Cells Requires the Sin3A Transcriptional Repressor

Molecular Cancer
Cancer ResearchOncologyMolecular Medicine
2010English

Identification of Insulin-Like Growth Factor-I Receptor (IGF-IR) Gene Promoter-Binding Proteins in Estrogen Receptor (ER)-Positive and ER-Depleted Breast Cancer Cells

Cancers
Cancer ResearchOncology
2010English

HLA Epitope Mismatch in T Cell-Replete Haploidentical Hematopoietic Cell Transplantation Is Associated With Worse Relapse Free Survival and Longer Engraftment

Biology of Blood and Marrow Transplantation
TransplantationHematology
2018English

Improved Relapse-Free Survival on Aromatase Inhibitors in Breast Cancer Is Associated With Interaction Between Oestrogen Receptor-Α and Progesterone Receptor-B

British Journal of Cancer
Cancer ResearchOncology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy